{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:25Z","timestamp":1791395605813,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01304-0","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:10:05Z","timestamp":1791393005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statistical Tools for Biosimilarity Assessment: A Perspective Based on WHO-recommended Approaches"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4244","authenticated-orcid":false,"given":"Anurag S.","family":"Rathore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1304_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh G, Walsh E, Nature Publishing Group. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40:1722\u201360. https:\/\/doi.org\/10.1038\/s41587-022-01582-x.","journal-title":"Nat Biotechnol"},{"key":"1304_CR2","doi-asserted-by":"crossref","unstructured":"Rathore AS, Gardner PJ, Chhabra H, Raman R. Global outlook on affordability of biotherapeutic drugs 2024 - Annals of the New York Academy of Sciences - Wiley Online Library. https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/abs\/10.1111\/nyas.15171. Accessed 9 Feb 2026.","DOI":"10.1111\/nyas.15171"},{"key":"1304_CR3","unstructured":"Biological Product Innovation and Competition. FDA; 2024. https:\/\/www.fda.gov\/drugs\/biosimilars\/biological-product-innovation-and-competition.\u00a0Accessed 9 Feb 2026."},{"key":"1304_CR4","unstructured":"Multidisciplinary: biosimilar | European Medicines Agency (EMA) 2010. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-biosimilar. Accessed 31 Jul 2025."},{"key":"1304_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31:175\u201387. https:\/\/doi.org\/10.1007\/s40259-017-0218-5.","journal-title":"BioDrugs"},{"key":"1304_CR6","unstructured":"Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry | FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality. Accessed 9 Feb 2026."},{"key":"1304_CR7","unstructured":"Biosimilars. U.S. Food and Drug Administration FDA; 2023. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars. Accessed 9 Jan 2025."},{"key":"1304_CR8","unstructured":"Guidelines on evaluation of biosimilars. World Health Organization WHO; 2022. https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-evaluation-of-biosimilars. Accessed 12 Jan 2025."},{"key":"1304_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40259-023-00591-9","volume":"37","author":"H Kim","year":"2023","unstructured":"Kim H, Hong E, Lee J, Hong S, Kim J, Cho M, et al. Characterization for the similarity assessment between proposed biosimilar SB12 and eculizumab reference product using a state-of-the-art analytical method. BioDrugs. 2023;37:569\u201381. https:\/\/doi.org\/10.1007\/s40259-023-00591-9.","journal-title":"BioDrugs"},{"key":"1304_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1208\/s12248-016-9882-5","volume":"18","author":"S-C Chow","year":"2016","unstructured":"Chow S-C, Song F, Bai H. Analytical similarity assessment in biosimilar studies. AAPS J. 2016;18:670\u20137. https:\/\/doi.org\/10.1208\/s12248-016-9882-5.","journal-title":"AAPS J"},{"key":"1304_CR11","unstructured":"Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry FDA; 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product. Accessed 31 Jul 2025."},{"issue":"6","key":"1304_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/03007995.2022.2061707","volume":"38","author":"SS Agarwala","year":"2022","unstructured":"Agarwala SS, Nagl U, Guo X, Bellon A, Heyn J, Dimova-Dobreva M, et al. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar. Curr Med Res Opin. 2022;38(6):999\u20131009. https:\/\/doi.org\/10.1080\/03007995.2022.2061707.","journal-title":"Curr Med Res Opin"},{"key":"1304_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/19420862.2017.1402996","volume":"10","author":"N Nupur","year":"2018","unstructured":"Nupur N, Chhabra N, Dash R, Rathore AS. Assessment of structural and functional similarity of biosimilar products: rituximab as a case study. MAbs. 2018;10:143\u201358. https:\/\/doi.org\/10.1080\/19420862.2017.1402996.","journal-title":"MAbs"},{"key":"1304_CR14","doi-asserted-by":"publisher","first-page":"123896","DOI":"10.1016\/j.jchromb.2023.123896","volume":"1229","author":"S Bhattacharya","year":"2023","unstructured":"Bhattacharya S, Rathore AS. Assessment of structural and functional similarity of biosimilar products: bevacizumab as a case study. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1229:123896. https:\/\/doi.org\/10.1016\/j.jchromb.2023.123896.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1304_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.biologicals.2016.06.005","volume":"44","author":"N Alt","year":"2016","unstructured":"Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44:291\u2013305. https:\/\/doi.org\/10.1016\/j.biologicals.2016.06.005.","journal-title":"Biologicals"},{"key":"1304_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijbiomac.2022.12.011","volume":"227","author":"AS Rathore","year":"2023","unstructured":"Rathore AS, Joshi S, Nupur N, Saxena N, Bhattacharya S, Roy S. Taking the individual bias out of examining comparability of biosimilars: a case study on monoclonal antibody therapeutics. Int J Biol Macromol. 2023;227:124\u201333. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.12.011.","journal-title":"Int J Biol Macromol"},{"key":"1304_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40268-023-00432-8","volume":"23","author":"D Cao","year":"2023","unstructured":"Cao D, Deng C, Wang G, Mei X, Xie J, Liu Y, et al. Physicochemical and functional similarity assessment between proposed bevacizumab biosimilar BAT1706 and reference bevacizumab. Drugs R D. 2023;23:267\u201388. https:\/\/doi.org\/10.1007\/s40268-023-00432-8.","journal-title":"Drugs R D"},{"key":"1304_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/ejhpharm-2016-001022","volume":"24","author":"A Planinc","year":"2017","unstructured":"Planinc A, Dejaegher B, Vander Heyden Y, Viaene J, Van Praet S, Rappez F, et al. Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab. Eur J Hosp Pharm. 2017;24:286\u201392. https:\/\/doi.org\/10.1136\/ejhpharm-2016-001022.","journal-title":"Eur J Hosp Pharm"},{"key":"1304_CR19","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1021\/acs.molpharmaceut.3c01157","volume":"21","author":"D Sarin","year":"2024","unstructured":"Sarin D, Krishna K, Nejadnik MR, Suryanarayanan R, Rathore AS. Impact of excipient extraction and buffer exchange on recombinant monoclonal antibody stability. Mol Pharm. 2024;21:1872\u201383. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01157.","journal-title":"Mol Pharm"},{"key":"1304_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40259-020-00404-3","volume":"34","author":"S Joshi","year":"2020","unstructured":"Joshi S, Rathore AS. Assessment of structural and functional comparability of biosimilar products: Trastuzumab as a case study. BioDrugs. 2020;34:209\u201323. https:\/\/doi.org\/10.1007\/s40259-020-00404-3.","journal-title":"BioDrugs"},{"key":"1304_CR21","doi-asserted-by":"publisher","unstructured":"Sample Size Requirements for Tolerance Intervals, Tolerance Bounds, and Related Demonstration Tests. Statistical Intervals. John Wiley & Sons, Ltd; 2017, p. 163\u201375. https:\/\/doi.org\/10.1002\/9781118594841.ch9.","DOI":"10.1002\/9781118594841.ch9"},{"key":"1304_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0167-7152(84)90071-3","volume":"2","author":"Y-M Chou","year":"1984","unstructured":"Chou Y-M, Mee RW. Determination of sample sizes for setting \u03b2-content tolerance limits controlling both tails of the normal distribution. Stat Probab Lett. 1984;2:311\u20134. https:\/\/doi.org\/10.1016\/0167-7152(84)90071-3.","journal-title":"Stat Probab Lett"},{"key":"1304_CR23","unstructured":"Statistical methodology for the comparative assessment of quality attributes in drug development - Scientific guideline | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/statistical-methodology-comparative-assessment-quality-attributes-drug-development-scientific-guideline. Accessed 9 Feb 2026."},{"key":"1304_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/biologics2030014","volume":"2","author":"SK Niazi","year":"2022","unstructured":"Niazi SK. Biosimilars: harmonizing the approval guidelines. Biologics. 2022;2:171\u201395. https:\/\/doi.org\/10.3390\/biologics2030014.","journal-title":"Biologics"},{"key":"1304_CR25","doi-asserted-by":"publisher","first-page":"832059","DOI":"10.3389\/fbioe.2022.832059","volume":"10","author":"N Nupur","year":"2022","unstructured":"Nupur N, Joshi S, Gulliarme D, Rathore AS. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front Bioeng Biotechnol. 2022;10:832059. https:\/\/doi.org\/10.3389\/fbioe.2022.832059.","journal-title":"Front Bioeng Biotechnol"},{"key":"1304_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/10543406.2016.1272606","volume":"27","author":"Y Tsong","year":"2017","unstructured":"Tsong Y, Dong X, Shen M. Development of statistical methods for analytical similarity assessment. J Biopharm Stat. 2017;27:197\u2013205. https:\/\/doi.org\/10.1080\/10543406.2016.1272606.","journal-title":"J Biopharm Stat"},{"issue":"suppl_4","key":"1304_CR27","doi-asserted-by":"publisher","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","volume":"56","author":"AG Vulto","year":"2026","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2026;56(suppl_4):iv14.","journal-title":"Rheumatology (Oxford)"},{"key":"1304_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/19420862.2018.1440170","volume":"10","author":"J Lee","year":"2018","unstructured":"Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs. 2018;10:547\u201371. https:\/\/doi.org\/10.1080\/19420862.2018.1440170.","journal-title":"MAbs"},{"key":"1304_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060527","author":"A Oliva","year":"2021","unstructured":"Oliva A, Llabr\u00e9s M. New quality-range-setting method based on between- and within-batch variability for biosimilarity assessment. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14060527.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1304_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2021.1889511","volume":"22","author":"AS Rathore","year":"2022","unstructured":"Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther. 2022;22:133\u201348. https:\/\/doi.org\/10.1080\/14712598.2021.1889511.","journal-title":"Expert Opin Biol Ther"},{"key":"1304_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nbt.1839","volume":"29","author":"M Schiestl","year":"2011","unstructured":"Schiestl M, Stangler T, Torella C, \u010cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310\u20132. https:\/\/doi.org\/10.1038\/nbt.1839.","journal-title":"Nat Biotechnol"},{"key":"1304_CR32","doi-asserted-by":"publisher","first-page":"e1903","DOI":"10.1097\/MJT.0000000000000391","volume":"23","author":"L Isakov","year":"2016","unstructured":"Isakov L, Jin B, Jacobs IA. Statistical primer on biosimilar clinical development. Am J Ther. 2016;23:e1903. https:\/\/doi.org\/10.1097\/MJT.0000000000000391.","journal-title":"Am J Ther"},{"key":"1304_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2144\/btn-2019-0031","volume":"67","author":"JR White","year":"2019","unstructured":"White JR, Abodeely M, Ahmed S, Debauve G, Johnson E, Meyer DM, et al. Best practices in bioassay development to support registration of biopharmaceuticals. Biotechniques. 2019;67:126\u201337. https:\/\/doi.org\/10.2144\/btn-2019-0031.","journal-title":"Biotechniques"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01304-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:10:08Z","timestamp":1791393008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01304-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01304-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests or conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"165"}}